| 1Z57 |
1.7 |
Crystal structure of human CLK1 in complex with 10Z-Hymenialdisine |
| 2VAG |
1.8 |
Crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor |
| 5J1V |
2.52 |
Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13) |
| 5J1W |
2.42 |
Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW31 (compound 14) |
| 5X8I |
1.902 |
Crystal structure of human CLK1 in complex with compound 25 |
| 6FT8 |
1.45 |
Crystal structure of CLK1 in complex with inhibitor 8g |
| 6FT9 |
1.87 |
Crystal structure of CLK1 in complex with inhibitor 16 |
| 6FYO |
2.32 |
X-RAY STRUCTURE OF CLK1-KD(148-484)/Cpd-2 AT 2.32A |
| 6G33 |
2.05 |
Crystal structure of CLK1 in complex with 5-iodotubercidin |
| 6I5H |
1.49 |
Crystal structure of CLK1 in complex with furanopyrimidin VN412 |
| 6I5I |
1.6 |
Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound 12h |
| 6I5K |
2.3 |
Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN345 (derivative of compound 12h) |
| 6I5L |
2.55 |
Crystal structure of CLK1 in complexed with furo[3,2-b]pyridine compound VN316 (derivative of compound 12h) |
| 6KHD |
2.7 |
Crystal structure of CLK1 in complex with CX-4945 |
| 6Q8K |
2.29 |
CLK1 with bound pyridoquinazoline |
| 6Q8P |
3.0 |
Structure of CLK1 with bound N-methyl-10-nitropyrido[3,4-g]quinazolin-2-amine |
| 6QTY |
1.65 |
Non-phosphorylated human CLK1 in complex with an indole inhibitor to 1.65 Ang |
| 6R3D |
1.85 |
Crystal structure of di-phosphorylated human CLK1 in complex with 4-(6,7-dichloro-1H-indol-3-yl)pyrimidin-2-amine |
| 6R6E |
2.25 |
Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1-methyl-1H-indol-3-yl)pyrimidin-4-amine |
| 6R6X |
2.05 |
Crystal structure of di-phosphorylated human CLK1 in complex with 5-(1-methyl-1H-indol-3-yl)pyrimidin-4-amine |
| 6R8J |
1.75 |
Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine |
| 6RAA |
2.1 |
CLK1 Kinase domain with bound imidazopyridin inhibitor TP003 |
| 6TW2 |
1.8 |
Re-refined crystal structure of di-phosphorylated human CLK1 in complex with a novel substituted indole inhibitor |
| 6YTA |
2.3 |
CLK1 bound with imidazopyridazine (Cpd 1) |
| 6YTD |
2.0 |
CLK1 V324A mutant bound with benzothiazole Tg003 (Cpd 2) |
| 6YTE |
2.3 |
CLK1 bound with benzothiazole Tg003 (Cpd 2) |
| 6YTG |
1.95 |
CLK1 bound with beta-carboline KH-CARB13 (Cpd 3) |
| 6YTI |
2.4 |
CLK1 bound with ETH1610 (Cpd 17) |
| 6Z4Z |
2.07 |
Crystal structure of CLK1 in complex with macrocycle ODS2004070 |
| 6Z50 |
1.6 |
Crystal structure of CLK1 in complex with macrocycle ODS2003208 |
| 6ZLN |
1.7 |
CLK1 bound with GW807982X (Cpd 8) |
| 7AK3 |
2.5 |
CLK1 bound with CAF052 |
| 7O9Y |
1.66 |
Crystal structure of di-phosphorylated human CLK1 in complex with 4-(1H-indol-3-yl)pyrimidin-2-amine |
| 7OA0 |
1.81 |
Crystal structure of di-phosphorylated human CLK1 in complex with 5-(6,7-dichloro-1H-indol-3-yl)pyrimidin-4-amine |
| 7OPG |
1.93 |
Crystal structure of CLK1 in complex with compound 2 (CC513) |
